Lucid Diagnostics: Holding Onto Medicare Coverage Hopes [Seeking Alpha]
Lucid Diagnostics Inc. (LUCD)
Company Research
Source: Seeking Alpha
However, its adoption rate remains constrained by reimbursement policies, which is a variable that could be a decisive factor for its long-term success. Medicare's LCD is in the final stages, with a draft expected late 2025 and a potential final decision in 2026. LUCD's cash runway is tight, which is why they raised additional funding through a stock offering. But overall, I feel LUCD's valuation is quite expensive relative to its peers and in light of its risks. Thus, I lean towards a neutral “Hold” rating at these levels. quantic69/iStock via Getty Images Lucid Diagnostics Inc. ( NASDAQ: LUCD ) is a medical diagnostics firm that develops the EsoGuard DNA test and the EsoCheck device. These devices are intended to help with the early detection of esophageal precancer and cancer. So far, EsoGuard's early This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate
Show less
Read more
Impact Snapshot
Event Time:
LUCD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUCD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUCD alerts
High impacting Lucid Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
LUCD
News
- Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics (NASDAQ:LUCD) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking HonoreePR Newswire
- Lucid Diagnostics (NASDAQ:LUCD) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LUCD&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumPR Newswire
LUCD
Earnings
- 11/12/25 - Miss
LUCD
Sec Filings
- 11/12/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 10/10/25 - Form SCHEDULE
- LUCD's page on the SEC website